Nad+ Metabolism In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme present in every living cell, serving as both a critical electron carrier in mitochondrial energy production and an essential substrate for a diverse family of signaling enzymes. NAD+ levels decline significantly with aging—by approximately 50% between youth and old age in multiple tissues—and this decline is accelerated in [neurodegenerative /diseases[/[diseases[/diseases including [Alzheimer's disease[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (AD), [Parkinson's disease[/diseases/[parkinsons--TEMP--/diseases)--FIX-- (PD), [amyotrophic lateral sclerosis[/diseases/[als--TEMP--/diseases)--FIX-- (ALS), and [Huntington's disease[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- (HD) (Lautrup et al., 2019) (Cell et al., 2024) [1].
The therapeutic strategy of boosting NAD+ levels has emerged as one of the most promising approaches to combating age-related neurodegeneration. NAD+ augmentation addresses multiple pathological processes simultaneously—[mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--, impaired [DNA repair], defective autophagy/mitophagy, neuroinflammation, and [cellular senescence[/mechanisms/[cellular-senescence--TEMP--/mechanisms)--FIX--—making it an attractive disease-modifying strategy rather than a single-target intervention (Fang et al., 2025) (Trends et al., 2025) [2].
¶ NAD+ Biochemistry and Brain Function
NAD+ exists in two forms: oxidized (NAD+) and reduced (NADH). In energy metabolism, NAD+ serves as the primary electron acceptor in glycolysis and the TCA cycle, with NADH subsequently donating electrons to the mitochondrial electron transport chain (ETC) to drive oxidative phosphorylation and ATP synthesis. The brain, despite comprising only ~2% of body mass, consumes approximately 20% of total body glucose and oxygen, making it exquisitely dependent on NAD+-driven energy metabolism (Cell et al., 2016) [3].
Beyond energy metabolism, NAD+ serves as a consumed substrate (not merely a cofactor) for three major enzyme families:
The sirtuin family of NAD+-dependent protein deacetylases and deacylases regulate:
- [SIRT1[/genes/[sirt1--TEMP--/genes)--FIX--: Nuclear; deacetylates transcription factors (FOXO3, [NF-κB[/entities/[nf-kb--TEMP--/entities)--FIX--, p53, PGC-1α), promoting mitochondrial biogenesis, anti-inflammatory signaling, and autophagy
- SIRT2: Primarily cytoplasmic; regulates [microtubule dynamics] and myelination in oligodendrocytes
- SIRT3: Mitochondrial; master regulator of mitochondrial protein acetylation, oxidative stress defense (activates SOD2), and fatty acid oxidation
- SIRT5: Mitochondrial; regulates succinylation, critical for TCA cycle enzyme function
- SIRT6: Nuclear; essential for [DNA repair], telomere maintenance, and glucose homeostasis
PARP1 and PARP2 consume NAD+ to synthesize poly(ADP-ribose) chains on proteins at DNA damage sites. In neurodegeneration, chronic DNA damage leads to PARP hyperactivation, which can deplete cellular NAD+ pools—a phenomenon termed "NAD+ stealing." PARP1 hyperactivation has been documented in AD and PD brains and contributes to neuronal energy failure (Fang et al., 2021).
CD38 is the dominant NAD+ consumer in mammalian tissues. This ectoenzyme degrades NAD+ and its precursors (NMN, NR) through its NADase and cyclase activities. CD38 expression increases with aging and neuroinflammation:
- Inflammatory [microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--: NAMPT (nicotinamide phosphoribosyltransferase) catalyzes the rate-limiting conversion of nicotinamide (NAM) to NMN, which is then converted to NAD+ by NMNAT1-3. This pathway recycles the nicotinamide released by NAD+-consuming enzymes [4].
-
Preiss-Handler pathway: Converts dietary nicotinic acid (vitamin B3) to NAD+ via a three-step enzymatic process [4].
-
De novo synthesis (kynurenine pathway): Converts tryptophan to quinolinic acid and ultimately NAD+. This pathway intersects with the [kynurenine pathway[/mechanisms/[kynurenine-pathway--TEMP--/mechanisms)--FIX--, which is dysregulated in neurodegeneration—inflammatory activation shunts tryptophan metabolism toward neurotoxic quinolinic acid rather than NAD+ production [5].
NAD+ depletion in AD results from the convergence of multiple pathological processes:
- PARP1 hyperactivation: [amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers and tau] hyperphosphorylation cause DNA damage, triggering PARP1 overactivation that depletes NAD+ pools
- CD38 upregulation: neuroinflammation drives CD38 expression on activated [microglia[/[astrocytes[/astrocytes. A landmark 2025 study demonstrated that REV-ERBα regulates brain NAD+ via an NFIL3-CD38 axis, and disruption of this circadian regulatory circuit contributes to NAD+ depletion and tauopathy (Kim et al., 2025)
- NAMPT downregulation: The rate-limiting NAD+ biosynthetic enzyme is reduced in AD brain, particularly in the [hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--
- Mitochondrial dysfunction: Reduced ETC function impairs NAD+/NADH cycling, creating a vicious cycle of declining energy metabolism and increased oxidative DNA damage
Functionally, NAD+ depletion in AD impairs autophagy and mitophagy—clearance pathways essential for removing [amyloid plaques], [hyperphosphorylated tau], and damaged mitochondria. Restoration of NAD+ levels rescues defective mitophagy in AD model organisms, demonstrating the functional significance of this depletion (Fang et al., 2019) [6].
In PD, NAD+ deficiency intersects with [dopaminergic neurodegeneration[/mechanisms/[dopaminergic-neurodegeneration--TEMP--/mechanisms)--FIX--:
- [PINK1[/genes/[pink1--TEMP--/genes)--FIX--/[Parkin[/genes/[prkn--TEMP--/genes)--FIX-- pathway: NAD+ is required for SIRT1-mediated deacetylation of mitophagy regulators. NAD+ depletion impairs the PINK1/Parkin mitophagy pathway, leading to accumulation of damaged mitochondria in [dopaminergic [neurons[/entities/[neurons--TEMP--/entities)--FIX--
- [alpha-synuclein/proteins/alpha aggregation: NAD+ depletion reduces SIRT1/3 activity, increasing protein acetylation and promoting alpha
- Oxidative vulnerability: substantia nigra dopaminergic [neurons[/entities/[neurons--TEMP--/entities)--FIX-- have high basal oxidative stress from dopamine metabolism, making them especially sensitive to NAD+-dependent antioxidant defense mechanisms (SOD2 activation by SIRT3)
Clinical evidence supports NAD+ therapy: the NADPARK study demonstrated that high-dose NR (1000 mg/day) was safe and increased brain NAD+ levels measured by 31P-MRS in PD patients, with trends toward improved clinical scores (Brakedal et al., 2022) (The et al., 2022) [8].
NAD+ metabolism is disrupted in ALS through:
- [SOD1/proteins/sod1 mutations: Mutant SOD1 increases oxidative DNA damage, driving PARP1 activation and NAD+ consumption
- [TDP-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology: [TDP-43[/entities/[tdp-43--TEMP--/entities)--FIX-- proteinopathy] disrupts mitochondrial function and NAD+ homeostasis in [motor [neurons[/entities/[neurons--TEMP--/entities)--FIX--
- SARM1 activation: The [SARM1[/genes/[sarm1--TEMP--/genes)--FIX-- NADase drives programmed axon degeneration (Wallerian degeneration) by consuming axonal NAD+. SARM1 inhibition is a promising therapeutic strategy for ALS
[huntingtin)/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- polyglutamine expansion disrupts NAD+ metabolism:
- Mutant [huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- impairs PGC-1α transcriptional activity, reducing mitochondrial biogenesis
- NAMPT expression is reduced in [striatal] [medium spiny neurons[/cell-types/[medium-spiny-neurons--TEMP--/cell-types)--FIX--, the cell population most vulnerable in HD
- NAD+ supplementation rescues mitochondrial function and improves motor phenotypes in HD animal models
Two NAD+ precursors have been most extensively studied:
NR is converted to NMN by nicotinamide riboside kinases (NRK1/2), then to NAD+ by NMNATs (Cognitive et al., 2025):
- Preclinical data: NR restores mitophagy, reduces amyloid-β proteotoxicity, decreases [BACE1[/entities/[bace1--TEMP--/entities)--FIX-- (Wu et al., 2025)
- NADAPT trial: Phase 2 study testing high-dose NR (3000 mg/day) in atypical parkinsonism ([PSP[/diseases/[psp--TEMP--/diseases)--FIX--, [MSA[/diseases/[msa--TEMP--/diseases)--FIX--, corticobasal syndrome)
NMN is the direct precursor to NAD+, converted by NMNAT enzymes:
- Preclinical data: NMN restores NAD+ profiles and improves mitochondrial stress response through the ATF4-dependent mitochondrial unfolded protein response (UPRmt) in AD models (Fang et al., 2024)
- Intestinal barrier and brain: NMN reverses D-galactose-induced neurodegeneration and enhances intestinal barrier function via the Sirt1 pathway, highlighting the [Gut-Brain Axis[/mechanisms/[gut-brain-axis--TEMP--/mechanisms)--FIX-- connection
- Clinical translation: Multiple NMN supplementation trials are ongoing, though none have yet demonstrated robust cognitive endpoints in neurodegenerative populations
High-dose nicotinamide (vitamin B3) has been tested directly in AD:
- The NACT study (Phase 2) tested NAM 1500 mg twice daily in mild-to-moderate AD. Results showed no significant changes in CSF total tau], phosphorylated tau], or amyloid-β, though a nominally significant slowing of cognitive decline was observed
- NAM enters the NAD+ salvage pathway directly through NAMPT
Blocking CD38-mediated NAD+ degradation is emerging as a complementary or alternative strategy to precursor supplementation:
- Small molecule CD38 inhibitors (e.g., 78c, apigenin, quercetin): Increase NAD+ levels by blocking its degradation rather than increasing synthesis
- Anti-CD38 antibodies: A 2025 study showed that targeting CD38 restored metabolic fitness and improved cognition in AD mice, with reduced [microglial/cell-types/microglianeuroinflammation (Nature Communications, 2025
- Dual approach: Combining CD38 inhibition with NAD+ precursors may achieve greater NAD+ restoration than either strategy alone
Enhancing the rate-limiting step of NAD+ salvage:
- P7C3 compounds (e.g., P7C3-A20) activate NAMPT and restore NAD+ homeostasis without producing supraphysiologic NAD+ levels—a potential advantage over exogenous precursor flooding. P7C3-A20 has shown remarkable effects in reversing cognitive deficits and neuropathology in advanced AD mouse models (Pieper et al., 2025)
- SBI-797812 is a direct NAMPT activator under preclinical development
For axonal protection, particularly relevant to ALS and other motor neuron diseases:
- SARM1 is an NAD+ hydrolase that triggers axon degeneration when activated
- SARM1 inhibitors preserve axonal NAD+ and prevent [Wallerian degeneration[/mechanisms/[wallerian-degeneration--TEMP--/mechanisms)--FIX--
- Multiple pharmaceutical programs target SARM1 for ALS and peripheral neuropathy
Since many NAD+ benefits are mediated through sirtuins:
- Resveratrol and SRT2104 activate SIRT1, promoting mitochondrial function and anti-inflammatory signaling
- Honokiol activates SIRT3, protecting mitochondrial function in [neurons[/entities/[neurons--TEMP--/entities)--FIX--
- However, sirtuin activators cannot fully substitute for NAD+ restoration, as other NAD+-consuming enzymes (PARPs, CD38) also play important roles
¶ Challenges and Controversies
¶ Bioavailability and Brain Penetration
A critical question is whether orally administered NAD+ precursors effectively raise brain NAD+ levels (Nature et al., 2025):
- NR and NMN increase blood and peripheral tissue NAD+ in human studies
- Brain NAD+ measurement is challenging; 31P-MRS can estimate brain NAD+ but with limited sensitivity
- The NADPARK trial demonstrated that NR increases brain NAD+ in PD patients, providing important proof-of-concept
- Precursor metabolism may differ between periphery and brain, and CD38 in the vasculature can degrade circulating NMN
¶ Dosing and Duration
Optimal dosing remains uncertain:
- Most trials have used relatively short durations (8-12 weeks) and moderate doses
- Higher doses (3000 mg/day NR in NADAPT) may be needed for neurodegenerative conditions
- Long-term safety data are limited for high-dose regimens
- Individual variation in response (related to baseline NAD+, CD38 levels, genetic factors) may require personalized dosing
¶ NAD+ and Cancer Risk
A theoretical concern is that NAD+ augmentation could promote cancer cell survival and proliferation, since cancer cells also depend on NAD+ for rapid growth. However:
- Long-term supplementation studies have not shown increased cancer incidence
- The neuroprotective doses used in neurodegenerative disease trials are within the range of dietary vitamin B3 supplementation
- NAMPT inhibitors (which deplete NAD+) are being developed as anticancer agents, raising the question of whether NAD+ boosting could counteract cancer therapy in patients with both conditions
The complexity of NAD+ metabolism suggests that targeting a single node may be insufficient:
- Combining precursor supplementation with CD38 inhibition addresses both synthesis and degradation
- Adding sirtuin activators may amplify downstream signaling benefits
- Addressing the root causes of NAD+ decline (reducing PARP hyperactivation, controlling neuroinflammation) may be necessary for sustained benefit
¶ Current Research and Future Directions
The field is rapidly evolving with several key research directions:
- Circadian regulation of NAD+: NAD+ levels oscillate with circadian rhythms, and [circadian disruption[/mechanisms/[circadian-disruption--TEMP--/mechanisms)--FIX-- in neurodegeneration may compound NAD+ depletion. The REV-ERBα/NFIL3/CD38 axis represents a novel therapeutic target
- Cell-type-specific NAD+ metabolism: [Single-cell genomics[/technologies/[single-cell-genomics--TEMP--/technologies)--FIX-- approaches are revealing that NAD+ metabolism differs dramatically between [neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, [microglia[/[oligodendrocytes[/oligodendrocytes(/cell-types/oligodendrocytes)
- NAD+ biosensors: Genetically encoded NAD+ sensors enable real-time monitoring of NAD+ dynamics in living [neurons[/entities/[neurons--TEMP--/entities)--FIX--, advancing mechanistic understanding
- [Gut-Brain Axis[/mechanisms/[gut-brain-axis--TEMP--/mechanisms)--FIX--: The gut microbiome influences NAD+ metabolism, and NMN effects on the intestinal barrier may contribute to neuroprotection through reduced peripheral inflammation
- Biomarker development: [Plasma biomarkers[/diagnostics/[plasma-biomarkers--TEMP--/diagnostics)--FIX-- of NAD+ metabolites (NAD+, NMN, NAM, ADPR) could enable treatment monitoring and patient stratification
- Sex differences: NAD+ metabolism and response to supplementation may differ between sexes, potentially relating to hormonal regulation of NAMPT and CD38
The study of Nad+ Metabolism In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Lautrup, S., et al. (2019]. "NAD+ in Brain Aging and Neurodegenerative Disorders." Cell Reports, 29(10), 2786-2801. DOI
- [Fang, E.F., et al. (2025]. "NAD augmentation as a disease-modifying strategy for neurodegeneration." Trends in Endocrinology & Metabolism. DOI
- [Camacho-Pereira, J., et al. (2016]. "CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism." Cell Metabolism, 23(6), 1127-1139. DOI
- [Fang, E.F., et al. (2021]. "NAD+ in Alzheimer's Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo." Frontiers in Cell and Developmental Biology, 9, 668491. DOI
- [Brakedal, B., et al. (2022]. "The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's Disease." Cell Reports, 40(5), 110815. DOI
- [Kim, H., et al. (2025]. "REV-ERBα regulates brain NAD+ levels and tauopathy via an NFIL3-CD38 axis." Nature Aging. DOI
- [Wu, L., et al. (2025]. "Cognitive and Alzheimer's Disease biomarker effects of oral nicotinamide riboside supplementation." Alzheimer's & Dementia: Translational Research & Clinical Interventions. DOI
- [Nature Communications (2025]. "Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in a mouse model of Alzheimer's Disease." DOI
- [Pieper, A.A., et al. (2025]. "Pharmacologic reversal of advanced Alzheimer's Disease in mice and identification of potential therapeutic nodes in human brain." Cell Reports Medicine. DOI
- [Xie, X., et al. (2023]. "Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases." Neuroscience Bulletin, 39, 1-17. DOI
- [Chini, C.C.S., et al. (2024]. "NAD+ glycohydrolases-CD38 as a therapeutic target in aging." Biochemical Pharmacology. DOI: 10.1016/j.bcp.2025)
- Tur, J., et al. (2025]. "Unveiling the role of NAD glycohydrolase CD38 in aging and age-related diseases." Frontiers in Immunology, 16, 1579924.## External Links
-
-
-
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 43%